These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22465008)

  • 1. How do tumor stem cells actively escape from host immunosurveillance?
    Qi Y; Li RM; Kong FM; Li H; Yu JP; Ren XB
    Biochem Biophys Res Commun; 2012 Apr; 420(4):699-703. PubMed ID: 22465008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How do tumors actively escape from host immunosurveillance?
    Wilczyński JR; Duechler M
    Arch Immunol Ther Exp (Warsz); 2010 Dec; 58(6):435-48. PubMed ID: 20922572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-host immune interactions and dendritic cell dysfunction.
    Yang L; Carbone DP
    Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive cells in tumor immune escape and metastasis.
    Liu Y; Cao X
    J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.
    Poggi A; Musso A; Dapino I; Zocchi MR
    Immunol Lett; 2014; 159(1-2):55-72. PubMed ID: 24657523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
    Matsui S; Ahlers JD; Vortmeyer AO; Terabe M; Tsukui T; Carbone DP; Liotta LA; Berzofsky JA
    J Immunol; 1999 Jul; 163(1):184-93. PubMed ID: 10384115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between cancer stem cells, immune system and some environmental components: Friends or foes?
    Vahidian F; Duijf PHG; Safarzadeh E; Derakhshani A; Baghbanzadeh A; Baradaran B
    Immunol Lett; 2019 Apr; 208():19-29. PubMed ID: 30862442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical implications of antitumor immunity in head and neck cancer.
    Allen CT; Judd NP; Bui JD; Uppaluri R
    Laryngoscope; 2012 Jan; 122(1):144-57. PubMed ID: 22183634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma stem cells: targets for successful therapy?
    Houben R; Wischhusen J; Menaa F; Synwoldt P; Schrama D; Bröcker EB; Becker JC
    J Dtsch Dermatol Ges; 2008 Jul; 6(7):541-6. PubMed ID: 18513214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor escape from immune surveillance.
    Costello RT; Gastaut JA; Olive D
    Arch Immunol Ther Exp (Warsz); 1999; 47(2):83-8. PubMed ID: 10202560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance.
    Groth A; Klöss S; von Strandmann EP; Koehl U; Koch J
    J Innate Immun; 2011; 3(4):344-54. PubMed ID: 21576922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immune response and cancer].
    El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
    Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients.
    Huang XJ
    Best Pract Res Clin Haematol; 2011 Sep; 24(3):351-8. PubMed ID: 21925088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escape from immune- and nonimmune-mediated tumor surveillance.
    Malmberg KJ; Ljunggren HG
    Semin Cancer Biol; 2006 Feb; 16(1):16-31. PubMed ID: 16140546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural immunity to cancer in humans.
    Bindea G; Mlecnik B; Fridman WH; Pagès F; Galon J
    Curr Opin Immunol; 2010 Apr; 22(2):215-22. PubMed ID: 20207124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?
    Salih HR; Nüssler V
    Eur J Med Res; 2001 Aug; 6(8):323-32. PubMed ID: 11549514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Janus face of dendritic cells in cancer.
    Chaput N; Conforti R; Viaud S; Spatz A; Zitvogel L
    Oncogene; 2008 Oct; 27(45):5920-31. PubMed ID: 18836473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.
    Norde WJ; Maas F; Hobo W; Korman A; Quigley M; Kester MG; Hebeda K; Falkenburg JH; Schaap N; de Witte TM; van der Voort R; Dolstra H
    Cancer Res; 2011 Aug; 71(15):5111-22. PubMed ID: 21659460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The pattern recognition receptor-mediated immune tolerance is involved in tumor metastasis].
    Hu ZW; Yang HZ
    Sheng Li Ke Xue Jin Zhan; 2010 Feb; 41(1):5-10. PubMed ID: 21417007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
    Mocellin S; Nitti D
    Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.